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Edited by Judit Ova´diAbstract Synthesis and maintenance of primary cilia are regu-
lated by the von Hippel–Lindau (VHL) tumour suppressor pro-
tein. Recent studies indicate that this regulation is linked to
microtubule-dependent functions of pVHL such as orienting
microtubule growth and increasing plus-end microtubule stabil-
ity, however little is known how this occurs. We have identiﬁed
the kinesin-2 motor complex, known to regulate cilia, as a novel
and endogenous pVHL binding partner. The interaction with
kinesin-2 facilitates pVHL binding to microtubules. These data
suggest that microtubule-dependent functions of pVHL are inﬂu-
enced by kinesin-2.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The rare hereditary von Hippel–Lindau (VHL) disease is
caused by heterozygous germline mutations in the VHL gene
[1], which predisposes patients to a variety of cysts and tu-
mours. Multifocal renal cysts exhibit loss of VHL heterozygos-
ity [2]; moreover, kidney-speciﬁc inactivation of vhl in mice
results in the development of kidney cysts [3]. Both isoforms,
pVHL30 and pVHL19, function as an ubiquitin E3 ligase, tar-
geting hydroxylated hypoxia inducible factor alpha (HIFa) for
poly-ubiquitination and subsequent proteasomal degradationAbbreviations: pVHL, von Hippel–Lindau tumour suppressor protein;
HIFa, hypoxia inducible factor alpha; MT, microtubules; DFO,
desferoxamine; IVTT, in vitro transcription/translation
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doi:10.1016/j.febslet.2007.08.050[1,4,5]. Hypoxia interferes with HIFa-hydroxylation, thereby
enabling stabilised HIFa to transactivate genes necessary for
adjusting to a hypoxic environment.
Recent studies support a function for pVHL in the primary
cilium [6,7]. The axoneme core of cilia serves as tubulin scaf-
folding for the kinesin-2 complex, which transports all cargo
into the cilium [8]. Accordingly, genetic disruption of any of
the individual components of the kinesin-2 complex (KIF3A,
KIF3B, and KAP3) invariably results in cilia dysfunction and
renal cyst development [9]. Here, we report the identiﬁcation
of kinesin-2 as novel and endogenous pVHL binding part-
ner, mediating binding to microtubules (MT). Since pVHL
and kinesin-2 have overlapping functions regarding primary
cilia regulation, these data may provide novel mechanistic
insight into MT-dependent regulation of primary cilia by
pVHL.2. Materials and methods
2.1. Construction of plasmids
All expression constructs were generated using pcDNA3-derived
vectors (Promega, USA) containing either N-terminal Myc- or Vsv-
tag by standard cloning techniques. GFP-fusion constructs were gener-
ated by cloning into pEGFP-C1/2 (Clontech, USA). KIF3A (gift from
Dr. L. Goldstein), KIF3B, DN-KAP3 (gift from Dr. T. Akiyama),
VHL-D95-123 and VHL-Y112H (gift from Dr. W. Krek) constructs
were cloned into the appropriate vectors. pBABE-puro was a gift from
Dr. G. Nolan.2.2. Yeast-two-hybrid screen
A human fetal brain cDNA library (Matchmaker, Clontech) was co-
transfected with VHL-pMD4 into Saccharomyces cerevisiae strain
Hf7c. Plasmids were recovered from His+/LacZ+ clones and tested
for speciﬁcity with irrelevant baits and 2.5 mM or 25 mM of 3-amino-
triazole (3AT).2.3. Cell culture
HEK293T, MDCK, murine neuroblastoma N1E-115 cells, and mur-
ine C26 colorectal carcinoma cells were cultured in DMEM supple-
mented with antibiotics and 5–10% fetal calf serum. Primary kidney
cells were isolated from 4-day-old mice by sequential trypsinisation
steps and cultured in DMEM supplemented with antibiotics and
20% fetal calf serum to conﬂuency. Cells cultured to produce cilia,
received serum-free medium for an additional 3 days after reaching
conﬂuency to stimulate cilia outgrowth. Transfections were performed
using Fugene-6 (Boehringer Mannheim, Germany). MG132 (5 lM;
Sigma–Aldrich, USA) was used for 8 h to inhibit proteasomal degrada-
tion. Desferoxamine (DFO) (100 lM; Sigma–Aldrich) was used for 4 h
to stabilise HIFa.blished by Elsevier B.V. All rights reserved.
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After 24 h transfection with the indicated pBABE plasmids, Phoenix
ecotropic packaging cells (gift from Dr. G. Nolan) were incubated at
32 C for 24 h before harvesting culture supernatants. N1E-115 orFig. 1. pVHL interacts with kinesin-2. (A) Yeast-two-hybrid assay with Gal
and b-domain of pVHL (VHLb), the a-domain of pVHL (VHLa) or pVHL
panel: colony growth of transformed yeast, using increasing 3-aminotriazole
in the presence of histidine. (B) Western blot analysis of IVTT Myc-KIF3A
control. wcl, whole cell lysates; HC, immunoglobin heavy chain. IB, immuno
and pVHL recovery after a-RPTPl, a-VHL and a-KIF3A IPs in VHL-deﬁcie
cells stained for acetylated tubulin (red), demonstrate cilia (arrows) when u
pVHL30 to multiple cilia in MDCK cells. DAPI (blue) stains nuclei. (E) pVHL
images of BMK and MDCK cells transfected with GFP-pVHL30 co-localis
with endogenous pVHL. DAPI (blue) stains nuclei. (F) Exogenous KIF3A
MG132 treatment.C26 cells were transduced with sterile-ﬁltered culture supernatants
24–36 h at 32 C with 8 lg/ml polybrene. Fresh medium supplemented
with puromycin (1 lg/ml; Sigma–Aldrich) replaced the supernatants
for an additional 24 h at 37 C.4 DNA binding domain fused to: full-length pVHL (VHLﬂ), the acidic
lacking exon 2 (VHLD2) used as bait and KIF3A used as prey. Right
(3AT; 0, 12.5 and 25 mM) without histidine (-HIS). Control colony (c)
binding to IVTT Vsv-pVHL30. a-RPTPl serves as unrelated antibody
blot. (C) Western blot analysis of endogenous KAP3, KIF3B, KIF3A
nt C26 cells and ciliated baby mouse kidney (BMK). Right panel, BMK
sed for IP. DAPI (blue) stains nuclei. (D) Translocalisation of GFP-
30 co-localises with a subset of ciliary KIF3A in kidney cells. Confocal
ing with endogenous KIF3A and conversely, GFP-KIF3A co-localises
does not accumulate or become poly-ubiquitinated like HIF1a after
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Approximately 1 · 106 cells were lysed in 400 ll buﬀer (20 mM
TRIS, 1% Triton-X-100, 140 mM NaCl, 10% glycerol, pH 8.0) with
protease inhibitors (Roche, Switzerland), then centrifuged 10 min at
13000 rpm. Mouse monoclonal a-VHL (1.5 lg; Ig32; BD-Pharmingen,
USA) coupled to protein A/G agarose beads (7.5 ll; Santa-Cruz Bio-
technology, USA), was added to 170 ll cleared lysate. For endogenous
IPs, 1 · 107 cells were lysed in 400 ll buﬀer of which 100 ll fresh
cleared lysate was added to 25 ll protein A/G agarose beads pre-cou-
pled to 7.5 lg mouse monoclonal a-VHL, 7.5 lg mouse monoclonal a-
KIF3A (BD-Transduction Labs, USA), or 7.5 lg mouse monoclonal
a-RPTPl (clone 3D7) for speciﬁcity control. IPs were incubated 4 h
at RT, washed three times and analysed by Western blot. In vitro tran-
scription/translation (IVTT) samples were generated according to
manufacturer’s protocol (Promega).
2.6. Immunoﬂuorescence staining
Fixed cells were incubated with a-KIF3A (1:500; BD-Transduction
Labs), a-acetylated tubulin (1:20000; Sigma–Aldrich) or a-VHL
(1:500; Ig32, BD-Pharmingen). Goat-anti-mouse Alexa568 (1:400,
Molecular probes, USA) was used as secondary antibody, as previ-
ously described [10].
2.7. Western blotting
Standard western blots [11] were incubated with a-Myc (9E10,
hybridoma supernatant 1:5), a-Vsv (P4D5, hybridoma supernatant
1:5), a-VHL (1:500, Ig32, BD-Pharmingen), a-KIF3A, a-KIF3B, a-
KAP3 (1:500; BD-Transduction Labs), anti-HIF1a (1:500, BD-Pharm-
ingen) or a-MAPK (1:500, gift from Dr. O. Kranenburg).
2.8. Microtubule co-sedimentation assays
Transfected HEK293T cells were lysed in PTN buﬀer (10 mM Pipes,
30 mM TRIS, 50 mM NaCl, 1 mM EGTA, 1.25 mM EDTA, 1 mM
DTT, 1% Triton-X-100, protease inhibitors, pH 6.3). IVTT samples
were generated according to manufacturer’s protocol (Promega).Fig. 2. Characterising pVHL-kinesin-2 interaction. (A) a-VHL IPs of retro
endogenous KIF3A and KAP3. Second and third panels, co-precipitation
recovery. LC, immunoglobin light chains. (B) Schematic representation of pLysates were pre-cleared by centrifugation at 100000 · g for 45 min.
Co-sedimentation assays were performed using the MAP Spin-down
Biochem Kit (Cytoskeleton, USA) with the following adjustments:
polymerised MT were centrifuged at 100000 · g for 30 min before
being resuspended in pre-cleared lysates containing 50 lM paclitaxel
and AMP–PNP (Sigma–Aldrich; ﬁnal concentration 10 mM) where
indicated, and incubated for 30 min. Samples were loaded onto
100 ll of the kit’s cushion buﬀer and centrifuged at 100000 · g for
40 min. Pre-cleared lysates, supernatant and pellet fractions were ana-
lysed by western blot.
2.9. Reporter assays
HIF reporter assays were performed in duplicate with 0, 100, or
300 ng Myc-DN-KAP3 and/or 100 ng wild-type HIF1a as previously
described [11].3. Results
3.1. VHL interacts with kinesin-2
We performed a yeast-two-hybrid screen of a human fetal
brain cDNA library with full-length pVHL as bait. Eight
clones bound pVHL robustly in this assay, including a known
pVHL interactor, chaperonin CCTg [12]. Interestingly, one of
the remaining clones has a strong link to cilia regulation:
KIF3A, component of the kinesin-2 microtubule motor
complex. We re-transformed yeast with KIF3A and four
diﬀerent pVHL bait constructs and determined that the ﬁrst
136 residues of pVHL largely determine this interaction
(Fig. 1A). Co-immunoprecipitation (IP) assays using
IVTTpVHL and KIF3A, validated the direct nature of this
interaction (Fig. 1B). Suggesting physiological relevance,virally reconstituted pVHL variants in C26 cells. Upper panel, input
of endogenous KAP3 and KIF3A, respectively. Lower panel, pVHL
VHL allelic variants and their ability to bind KIF3A and KAP3.
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KIF3A, KIF3B and KAP3 in ciliated primary mouse kidney
cells (Fig. 1C); likewise, a-KIF3A pulled down pVHL, while
an irrelevant antibody (a-RPTPl) did not retrieve either
pVHL or KIF3A (Fig. 1C). Confocal microscopy showed
endogenous pVHL or GFP-pVHL30 translocation to multiple
cilia in kidney cells partially overlapping with KIF3A localisa-
tion (Fig. 1D and E). Because pVHL functions as an E3 ubiq-
uitin ligase, we blocked proteasomal degradation with MG132
and observed no increased cellular levels or poly-ubiquitina-
tion of KIF3A (Fig. 1F). Taken together, these data suggest
endogenous interaction between pVHL and kinesin-2 in pri-
mary kidney cells, not aﬀecting KIF3A turnover.
3.2. Mutant VHL alleles do not bind kinesin-2
We characterised the binding of pVHL to kinesin-2 by test-
ing pVHL30, pVHL19, pVHL-D95-123, implicated in defectiveFig. 3. DN-KAP3 disrupts pVHL-KIF3A binding. (A) a-Vsv IPs of transfec
transfection eﬃciency for Myc-KIF3A and GFP-DN-KAP3. Second panel, M
panel, aspeciﬁc protein recovery in a-RPTPl IPs. Bottom panel, Vsv-pV
interaction. Upper panel, endogenous KAP3 and KIF3A. KIF3A IP shows
pBABE-puro with either no insert () or DN-KAP3 (+) speciﬁcally aﬀects KI
IPs are from the same blot, same exposure, but lanes have been rearranged to
KAP3. Upper panel shows endogenous HIF1a expression in HEK293T; lanes
indicated. Middle panel, expression Myc-DN-KAP3. Lower panel, MAPK l
ﬁlled bars) or mutated HRE (Mutant HRE-Luc; empty bars) with 0, 100 o
100 ng HIF1a was statistically signiﬁcant (P = 0.0004). NS, not signiﬁcant.regulation of MT stability [13] and pVHL-Y112H, a patient
missense mutation. Retroviral reconstitution of these VHL
allelic variants in VHL-deﬁcient C26 cells was conﬁrmed by
a-VHL IP and analysed for binding to endogenous KIF3A
and KAP3 (Fig. 2A). While transduced pVHL30 precipitated
endogenous KIF3A and KAP3, pVHL19 was less eﬀective at
co-precipitating KIF3A and failed to co-precipitate KAP3.
The opposite was true for the deletion variant pVHL-D95-
123 and the Y112H patient mutation, which failed to co-pre-
cipitate KIF3A, but recovered some KAP3. These data indi-
cate that the N-terminal acidic domain mediates binding of
pVHL30 to KAP3 and that the MT-binding domain is
required for KIF3A binding to pVHL (Fig. 2B).
3.3. pVHL-KIF3A binding does not aﬀect HIFa function
To experiment with the pVHL-KIF3A interaction, we
checked whether pVHL could bind a dominant-negative vari-ted Vsv-pVHL30 with Myc-KIF3A or GFP-DN-KAP3. Upper panel,
yc-KIF3A and GFP-DN-KAP3 recovery in a-Vsv IP fractions. Third
HL30 recovery. (B) DN-KAP3 disrupts endogenous pVHL-KIF3A
speciﬁc recovery of KIF3A (positive control). Retrovirally transduced
F3A recovery in a-VHL IPs. a-RPTPl, unrelated antibody control. All
improve presentation. (C) HIF1a response to DFO not aﬀected by DN-
treated with DFO or transfected with empty vector/Myc-DN-KAP3, as
oading control. (D) Hypoxia Response Element reporters (HRE-Luc;
r 300 ng Myc-DN-KAP3 with or without 100 ng HIF1a. Response to
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DN-KAP3), which disrupts binding between tumour suppres-
sor APC and kinesin-2 [14]. Indeed, exogenously expressed
Vsv-pVHL30 could co-precipitate GFP-tagged DN-KAP3
(Fig. 3A). To validate an eﬀect of DN-KAP3 on pVHL30-
KIF3A binding, a-VHL IPs were performed with N1E-115
cells either mock or DN-KAP3-transduced, and loss of endo-
genous binding between pVHL30 and KIF3A was observed
(Fig. 3B). DN-KAP3 however, does not aﬀect HIF1a stabilisa-
tion in response to DFO (Fig. 3C); nor are HIF responsive re-
porter assays aﬀected by increasing amounts of DN-KAP3
(Fig. 3D). Therefore, we concluded that the interaction be-
tween pVHL and KIF3A does not aﬀect HIF1a regulation
or function.
3.4. KIF3A increases pVHL binding to microtubules
To address the possibility that kinesin-2 mediates the previ-
ously reported binding of pVHL30 to MT [13], we performed
MT co-sedimentation assays with lysates of HEK293T cells
transfected with Vsv-pVHL30 (Fig. 4A). To determine
whether this association of pVHL with MT is direct, we
repeated this assay using highly puriﬁed tubulin and in vitroFig. 4. KIF3A mediates binding of pVHL to microtubules. (A) Left panels,
pellet (p) in a microtubule co-sedimentation assay. MT, microtubules. Lowe
using IVTT Vsv-pVHL30. Right panels, Coomassie Blue stainings of MT
(MAP2; serves as a positive control) and Bovine Serum albumin (BSA; serv
supernatant and pellet of microtubule spin down fractions without (upper p
transfected Vsv-pVHL30 from supernatant and pellet with or without MT. M
transfected with Vsv-pVHL30 and Myc-KIF3A. (D) Upper panel MT co-sedi
DN-KAP3 (60 kD). Expression Myc-DN-KAP3 shown on the left.translated full-length pVHL; yet pVHL30 never bound MT
in this assay. These data suggest that endogenous cellular fac-
tors, e.g. kinesin-2, enhance binding of pVHL to MT. Two
groups have previously performed microtubule co-sedimenta-
tion assays with pVHL. Most recently, Schermer et al. [15]
and Thoma et al. [7] show that cell lysates overexpressing
pVHL copelleted with polymerised tubulin; however, endo-
genous factors such as kinesin-2 are also present in these cell
lysates. Schermer et al. [15] also show that VHL IPs tubulin,
again in a lysate setting. The discrepancy between our data
and Hergovich’s published data using IVTTpVHL30 [13]
might be explained by diﬀerent protocols used in the two stud-
ies; we used a sucrose cushion in the co-sedimentation assay.
This sucrose cushion serves as a density gradient separating
the lysate from the pellet and increasing the speciﬁcity of the
spun down fraction. To address the diﬀerent outcomes, we di-
rectly compared the two methods with in vitro translated
pVHL30 in the presence or absence of a sucrose cushion sep-
aration. In the absence of the sucrose cushion we found more
pVHL in the pellet with MT than in the pellet without MT
(Fig. 4A). However, using the modiﬁed assay (with sucrose
cushion) we found no direct interaction between MT andtransfected vs. IVTT Vsv-pVHL30 recovered from supernatant (s) or
r panel, same assay repeated without the recommended cushion buﬀer
co-sedimentation controls tubulin, Microtubule-Associated Protein 2
es as a negative control). (B) Recovery of transfected Vsv-pVHL30 in
anel) or with AMP–PNP (lower panel). (C) Upper panel, recovery of
iddle and lower panel, recovery of pVHL and KIF3A using HEK293T
mentation of Vsv-pVHL30 transfected with empty vector or with Myc-
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3B require nucleotides for MT-binding, we repeated these as-
says in the presence of AMP–PNP, a non-hydrolysable form
of ATP. Treatment with AMP–PNP shifts more pVHL into
the pellet fraction (Fig. 4B) consistent with the involvement
of a motor protein in MT-binding by pVHL.
To study the eﬀect of KIF3A on MT-binding of pVHL, we
performed MT co-sedimentation assays using lysates of
HEK293T cells transfected with Vsv-pVHL30 and Myc-
KIF3A or empty vector. Myc-KIF3A enhanced binding of
Vsv-pVHL30 to MTs (Fig. 4C). Interestingly, co-transfecting
Vsv-pVHL30 with Myc-DN-KAP3 greatly reduced pVHL30
association with MTs (Fig. 4D).4. Discussion
Here we describe KIF3A as a novel pVHL binding partner
and conﬁrm direct binding between these proteins. Endo-
genous binding of pVHL to KIF3A and other subunits of
the anterograde kinesin-2 microtubule motor is also observed,
which can be compromised either by pVHL mutations or
by overexpression of a dominant-negative form of KAP3,
DN-KAP3. We identiﬁed two domains within pVHL to be
necessary for binding kinesin-2: the N-terminal acidic domain
(residues 1–54) facilitates KAP3 binding, and residues 95–123
bind KIF3A. How pVHL-DN-KAP3 binding prevents the
pVHL-moiety from simultaneous interaction with intact kine-
sin-2 could be explained by steric hindrance. Because pVHL
residues 95–123 have already been implicated in microtubule
binding [13], we performed microtubule co-sedimentation
assays and observed that a signiﬁcant portion – if not all –
of pVHL binding to MT is mediated through interaction with
kinesin-2. These ﬁndings correlate well with the regions and
mutations of pVHL described as being deﬁcient in stabilising
MT [13] and deﬁcient in maintaining primary cilia in kidney
epithelial cells [7], suggesting that kinesin-2 binding mediates
microtubule-related functions of pVHL.
Notably, KAP3 is the ﬁrst protein reported to bind the
acidic domain of pVHL. Phosphorylation of the acidic domain
has shown to be important for the full tumour suppressor
function of pVHL in mouse xenografts [16]. KAP3 has also
been shown to exert tumour suppressor function, as illustrated
by the malignant transformation of neural progenitor cells by
targeted deletion of KAP3 [17]. Whether these two tumour
suppressors inﬂuence each others’ function has yet to be deter-
mined.
Recent studies describe pVHL interaction with the cell
polarity complex Par3-Par6-aPKCf, [6]. Like pVHL, this com-
plex also regulates ciliogenesis, however Par3-Par6-aPKCf-
mediated ciliogenesis has been established to operate through
kinesin-2 [18]. A similar mechanism for pVHL-driven ciliogen-
esis has been hypothesised [6], however kinesin-2 binding to
pVHL could not be detected in their cell system. Our data adds
an unique element to ongoing studies concerning the role of
pVHL in cilia regulation.
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